FLT3 inhibitors at a concentration of 1000 nmol/L were effective in inhibiting growth of primary AML and CMML cells harbouring not only mutant CBL, but also other oncogenes, including ASXL1, RUNX1, IDH2, SRSF2, STAG2, AXL1 and TET2 (Table S1). The gene discussed is RUNX1; the disease is acute myeloid leukemia.